Johnson W J, Kyle R A, Pineda A A, O'Brien P C, Holley K E
Division of Nephrology, Mayo Clinic, Rochester, MN 55905.
Arch Intern Med. 1990 Apr;150(4):863-9.
The aims of this study were to examine in a prospective, randomized trial the efficacy of plasmapheresis in preventing irreversible renal failure in patients with multiple myeloma and to study the renal biopsy tissues from such patients. Twenty-one patients with active myeloma and progressive renal failure were randomized to one of two groups: group 1, forced diuresis and chemotherapy (10 patients), and group 2, forced diuresis, chemotherapy, and plasmapheresis (11 patients). Plasmapheresis and chemotherapy lowered the serum myeloma protein value much more rapidly than chemotherapy alone. Of 5 patients who were oliguric and undergoing dialysis at presentation, only 3 who were treated by plasmapheresis recovered. Of 16 polyuric patients, 5 in group 1 and 7 in group 2 showed improvement in renal function. The main factor that determined irreversibility of renal failure was the severity of myeloma cast formation.
本研究的目的是通过一项前瞻性随机试验,检验血浆置换术对预防多发性骨髓瘤患者不可逆肾衰竭的疗效,并研究此类患者的肾活检组织。21例活动性骨髓瘤和进行性肾衰竭患者被随机分为两组:第1组,强制利尿和化疗(10例患者),第2组,强制利尿、化疗和血浆置换术(11例患者)。血浆置换术和化疗比单纯化疗能更快地降低血清骨髓瘤蛋白值。5例就诊时少尿且正在接受透析的患者中,只有3例接受血浆置换术治疗后康复。16例多尿患者中,第1组5例和第2组7例肾功能有所改善。决定肾衰竭不可逆性的主要因素是骨髓瘤管型形成的严重程度。